These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
279 related articles for article (PubMed ID: 26679828)
61. A novel compound against oncogenic Aurora kinase A overcomes imatinib resistance in chronic myeloid leukemia cells. Long ZJ; Wang LX; Zheng FM; Chen JJ; Luo Y; Tu XX; Lin DJ; Lu G; Liu Q Int J Oncol; 2015; 46(6):2488-96. PubMed ID: 25872528 [TBL] [Abstract][Full Text] [Related]
62. Vandetanib drives growth arrest and promotes sensitivity to imatinib in chronic myeloid leukemia by targeting ephrin type-B receptor 4. Ma W; Zhu M; Wang B; Gong Z; Du X; Yang T; Shi X; Dai B; Zhan Y; Zhang D; Ji Y; Wang Y; Li S; Zhang Y Mol Oncol; 2022 Jul; 16(14):2747-2765. PubMed ID: 35689424 [TBL] [Abstract][Full Text] [Related]
63. Cysteine-rich protein 61 regulates the chemosensitivity of chronic myeloid leukemia to imatinib mesylate through the nuclear factor kappa B/Bcl-2 pathway. Song Y; Lin Q; Cai Z; Hao T; Zhang Y; Zhu X Cancer Sci; 2019 Aug; 110(8):2421-2430. PubMed ID: 31145521 [TBL] [Abstract][Full Text] [Related]
64. ZFX Facilitates Cell Proliferation and Imatinib Resistance in Chronic Myeloid Leukemia Cells. Wu J; Wei B; Wang Q; Ding Y; Deng Z; Lu X; Li Y Cell Biochem Biophys; 2016 Jun; 74(2):277-83. PubMed ID: 26912059 [TBL] [Abstract][Full Text] [Related]
65. Circ_0009910 promotes imatinib resistance through ULK1-induced autophagy by sponging miR-34a-5p in chronic myeloid leukemia. Cao HX; Miao CF; Sang LN; Huang YM; Zhang R; Sun L; Jiang ZX Life Sci; 2020 Feb; 243():117255. PubMed ID: 31923418 [TBL] [Abstract][Full Text] [Related]
66. [Suppression of NAMPT expression enhances the sensitivity of K562 cells to imatinib and its relative mechanism]. Lin PP; Bai XJ; Yue ZX; Yan SF; Li ZW; Gao C; Mei YY; Wang KL; Li WJ; Ding W; Li ZG Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Apr; 20(2):235-41. PubMed ID: 22541073 [TBL] [Abstract][Full Text] [Related]
67. Antileukemic activity of lysophosphatidic acid acyltransferase-beta inhibitor CT32228 in chronic myelogenous leukemia sensitive and resistant to imatinib. La Rosée P; Jia T; Demehri S; Härtel N; de Vries P; Bonham L; Hollenback D; Singer JW; Melo JV; Druker BJ; Deininger MW Clin Cancer Res; 2006 Nov; 12(21):6540-6. PubMed ID: 17085669 [TBL] [Abstract][Full Text] [Related]
68. Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate. Nguyen TK; Rahmani M; Gao N; Kramer L; Corbin AS; Druker BJ; Dent P; Grant S Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2239-47. PubMed ID: 16609040 [TBL] [Abstract][Full Text] [Related]
69. ABL SH3 mutant inhibits BCR-ABL activity and increases imatinib sensitivity by targeting RIN1 protein in CML cell. Liu X; Li Y; Wen L; Tao K; Xiao Q; Cao W; Huang Z; Gao M; Li H; Wang F; Feng W Cancer Lett; 2015 Dec; 369(1):222-8. PubMed ID: 26321052 [TBL] [Abstract][Full Text] [Related]
70. Preclinical model for identification of therapeutic targets for CML offers clues for handling imatinib resistance. Molli PR; Pradhan MB; Ingle AD; Naik NR Biomed Pharmacother; 2015 Jul; 73():160-70. PubMed ID: 26211598 [TBL] [Abstract][Full Text] [Related]
71. Distinct EphB4-mediated mechanisms of apoptotic and resistance to dasatinib in human chronic myeloid leukemia and K562 cell lines. Zhao WH; Huang BT; Zhang JY; Zeng QC Leuk Res; 2017 Dec; 63():28-33. PubMed ID: 29096333 [TBL] [Abstract][Full Text] [Related]
72. Anti-Leukemic Effects of Small Molecule Inhibitor of c-Myc (10058-F4) on Chronic Myeloid Leukemia Cells. Zehtabcheh S; Sheikh-Zeineddini N; Yousefi AM; Bashash D Asian Pac J Cancer Prev; 2024 Jun; 25(6):1959-1967. PubMed ID: 38918657 [TBL] [Abstract][Full Text] [Related]
73. Inhibition of the Nrf2-TrxR Axis Sensitizes the Drug-Resistant Chronic Myelogenous Leukemia Cell Line K562/G01 to Imatinib Treatments. Xu L; Zhao Y; Pan F; Zhu M; Yao L; Liu Y; Feng J; Xiong J; Chen X; Ren F; Tan Y; Wang H Biomed Res Int; 2019; 2019():6502793. PubMed ID: 31828114 [TBL] [Abstract][Full Text] [Related]
74. Cytokine-induced apoptosis inhibitor 1 inhibits the growth and proliferation of multiple myeloma. Wang X; Pan J; Li J Mol Med Rep; 2015 Aug; 12(2):2056-62. PubMed ID: 25901506 [TBL] [Abstract][Full Text] [Related]
75. Comparative study of the anti-leukemic effects of imatinib mesylate, Glivec™ tablet and its generic formulation, OHK9511. Yokoo M; Kubota Y; Tabe Y; Kimura S Biol Pharm Bull; 2015; 38(3):411-6. PubMed ID: 25757922 [TBL] [Abstract][Full Text] [Related]
76. Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin. Nimmanapalli R; O'Bryan E; Huang M; Bali P; Burnette PK; Loughran T; Tepperberg J; Jove R; Bhalla K Cancer Res; 2002 Oct; 62(20):5761-9. PubMed ID: 12384536 [TBL] [Abstract][Full Text] [Related]
77. Hydroxychavicol sensitizes imatinib-resistant chronic myelogenous leukemia cells to TRAIL-induced apoptosis by ROS-mediated IAP downregulation. Paul T; Banerjee A; Reddy SVB; Mahato SK; Biswas N Anticancer Drugs; 2019 Feb; 30(2):167-178. PubMed ID: 30418193 [TBL] [Abstract][Full Text] [Related]
78. Proteomics analysis reveals the correlation of programmed ROS-autophagy loop and dysregulated G1/S checkpoint with imatinib resistance in chronic myeloid leukemia cells. Xu X; Yin S; Ren Y; Hu C; Zhang A; Lin Y Proteomics; 2022 Jan; 22(1-2):e2100094. PubMed ID: 34564948 [TBL] [Abstract][Full Text] [Related]
79. Inhibition of YAP suppresses CML cell proliferation and enhances efficacy of imatinib in vitro and in vivo. Li H; Huang Z; Gao M; Huang N; Luo Z; Shen H; Wang X; Wang T; Hu J; Feng W J Exp Clin Cancer Res; 2016 Sep; 35(1):134. PubMed ID: 27599610 [TBL] [Abstract][Full Text] [Related]
80. Huai Qi Huang-induced Apoptosis via Down-regulating PRKCH and Inhibiting RAF/MEK/ERK Pathway in Ph Xu WF; Wang ZJ; Li K; Shen YQ; Lu K; Lv XY; Wen YX; Jin RM Curr Med Sci; 2020 Apr; 40(2):354-362. PubMed ID: 32337697 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]